These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 28202772)

  • 1. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
    Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
    Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.
    Mozneb M; Jenkins A; Sances S; Pohlman S; Workman MJ; West D; Ondatje B; El-Ghazawi K; Woodbury A; Garcia VJ; Patel S; Arzt M; Dezem F; Laperle AH; Moser VA; Ho R; Yucer N; Plummer J; Barrett RJ; Svendsen CN; Sharma A
    Lab Chip; 2024 Feb; 24(4):869-881. PubMed ID: 38252454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of mechanical conditioning into a high throughput contractility assay for cardiac safety assessment.
    Goßmann M; Linder P; Thomas U; Juhasz K; Lemme M; George M; Fertig N; Dragicevic E; Stoelzle-Feix S
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106892. PubMed ID: 32629160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hiPSC-CM Monolayer Maturation State Determines Drug Responsiveness in High Throughput Pro-Arrhythmia Screen.
    da Rocha AM; Campbell K; Mironov S; Jiang J; Mundada L; Guerrero-Serna G; Jalife J; Herron TJ
    Sci Rep; 2017 Oct; 7(1):13834. PubMed ID: 29061979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.
    Wang H; Sheehan RP; Palmer AC; Everley RA; Boswell SA; Ron-Harel N; Ringel AE; Holton KM; Jacobson CA; Erickson AR; Maliszewski L; Haigis MC; Sorger PK
    Cell Syst; 2019 May; 8(5):412-426.e7. PubMed ID: 31078528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
    Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
    Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
    Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
    Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy.
    Arzt M; Gao B; Mozneb M; Pohlman S; Cejas RB; Liu Q; Huang F; Yu C; Zhang Y; Fan X; Jenkins A; Giuliano AE; Burridge PW; Cui X; Sharma A
    Stem Cell Reports; 2023 Oct; 18(10):1913-1924. PubMed ID: 37657447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
    Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
    Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
    Scott CW; Zhang X; Abi-Gerges N; Lamore SD; Abassi YA; Peters MF
    Toxicol Sci; 2014 Dec; 142(2):331-8. PubMed ID: 25237062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac Toxicity From Ethanol Exposure in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Rampoldi A; Singh M; Wu Q; Duan M; Jha R; Maxwell JT; Bradner JM; Zhang X; Saraf A; Miller GW; Gibson G; Brown LA; Xu C
    Toxicol Sci; 2019 May; 169(1):280-292. PubMed ID: 31059573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.
    Wei F; Pourrier M; Strauss DG; Stockbridge N; Pang L
    Toxicol Sci; 2020 Apr; 174(2):254-265. PubMed ID: 32040191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human-induced pluripotent stem cell-derived cardiomyocytes from cardiac progenitor cells: effects of selective ion channel blockade.
    Altomare C; Pianezzi E; Cervio E; Bolis S; Biemmi V; Benzoni P; Camici GG; Moccetti T; Barile L; Vassalli G
    Europace; 2016 Dec; 18(suppl 4):iv67-iv76. PubMed ID: 28011833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells in Phenotypic Screening: A Transforming Growth Factor-β Type 1 Receptor Kinase Inhibitor Induces Efficient Cardiac Differentiation.
    Drowley L; Koonce C; Peel S; Jonebring A; Plowright AT; Kattman SJ; Andersson H; Anson B; Swanson BJ; Wang QD; Brolen G
    Stem Cells Transl Med; 2016 Feb; 5(2):164-74. PubMed ID: 26683871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yohimbine Directly Induces Cardiotoxicity on Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Gong Y; Yang L; Tang J; Zheng J; Witman N; Jakob P; Tan Y; Liu M; Chen Y; Wang H; Fu W; Wang W
    Cardiovasc Toxicol; 2022 Feb; 22(2):141-151. PubMed ID: 34817810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte (hiPSC-CM) Multielectrode Array Assay for Preclinical Cardiac Electrophysiology Safety Screening.
    Harris K
    Curr Protoc Pharmacol; 2015 Dec; 71():11.18.1-11.18.15. PubMed ID: 26646193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.